A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

被引:21
作者
Barlaam, Bernard [1 ]
Ballard, Peter [2 ]
Bradbury, Robert H. [2 ]
Ducray, Richard [1 ]
Germain, Herve [1 ]
Hickinson, D. Mark [2 ]
Hudson, Kevin [2 ]
Kettle, Jason G. [2 ]
Klinowska, Teresa [2 ]
Magnien, Francoise [1 ]
Ogilvie, Donald J. [2 ]
Olivier, Annie [1 ]
Pearson, Stuart E. [2 ]
Scott, James S. [2 ]
Suleman, Abid [2 ]
Trigwell, Cath B. [2 ]
Vautier, Michel [1 ]
Whittaker, Robin D. [2 ]
Wood, Robin [2 ]
机构
[1] AstraZeneca, Ctr Rech, F-51689 Reims 2, France
[2] AstraZeneca, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England
关键词
anilinoquinazoline; C-5; substitution; erbB2 kinase inhibitor;
D O I
10.1016/j.bmcl.2007.11.052
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:674 / 678
页数:5
相关论文
共 16 条
[1]   Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling [J].
Balani, SK ;
Li, P ;
Nguyen, J ;
Cardoza, K ;
Zeng, H ;
Mu, DX ;
Wu, JT ;
Gan, LS ;
Lee, FW .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) :1092-1095
[2]   Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket [J].
Ballard, P ;
Bradbury, RH ;
Harris, CS ;
Hennequin, LFA ;
Hickinson, M ;
Johnson, PD ;
Kettle, JG ;
Klinowska, T ;
Leach, AG ;
Morgentin, R ;
Pass, M ;
Ogilvie, DJ ;
Olivier, A ;
Warin, N ;
Williams, EJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1633-1637
[3]   5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase [J].
Ballard, P ;
Bradbury, RH ;
Hennequin, LFA ;
Hickinson, DM ;
Johnson, PD ;
Kettle, JG ;
Klinowska, T ;
Morgentin, R ;
Ogilvie, DJ ;
Olivier, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (19) :4226-4229
[4]   Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase [J].
Ballard, Peter ;
Barlaam, Bernard C. ;
Bradbury, Robert H. ;
Dishington, Allan ;
Hennequin, Laurent F. A. ;
Hickinson, D. Mark ;
Hollingsworth, Ian M. ;
Kettle, Jason G. ;
Klinowska, Teresa ;
Ogilvie, Donald J. ;
Pearson, Stuart E. ;
Scott, James S. ;
Suleman, Abid ;
Whittaker, Robin ;
Williams, Emma J. ;
Wood, Robin ;
Wright, Lindsay .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) :6326-6329
[5]   New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors [J].
Barlaam, B ;
Fennell, M ;
Germain, H ;
Green, T ;
Hennequin, L ;
Morgentin, R ;
Olivier, A ;
Plé, P ;
Vautier, M ;
Costello, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (24) :5446-5449
[6]  
Baselga J, 1998, CANCER RES, V58, P2825
[7]   EGF-ERBB signalling: towards the systems level [J].
Citri, Ami ;
Yarden, Yosef .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (07) :505-516
[8]  
Emens LA, 2004, ONCOLOGY-NY, V18, P1117
[9]   Targeting the HER-kinase axis in cancer [J].
Gross, ME ;
Shazer, RL ;
Agus, DB .
SEMINARS IN ONCOLOGY, 2004, 31 (01) :9-20
[10]   N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor [J].
Hennequin, Laurent F. ;
Allen, Jack ;
Breed, Jason ;
Curwen, Jon ;
Fennell, Michael ;
Green, Tim P. ;
Brempt, Christine Lambert-van der ;
Morgentin, Remy ;
Norman, Richard A. ;
Olivier, Annie ;
Otterbein, Ludovic ;
Ple, Patrick A. ;
Warin, Nicolas ;
Costello, Gerard .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (22) :6465-6488